BEST试验:血管内治疗与标准药物治疗椎基底动脉闭塞的比较
BEST试验是一项在中国28个中心进行的多中心、随机、开放标签、盲法结局评估研究,纳入131例椎基底动脉闭塞8小时内患者,比较血管内治疗联合标准药物与单纯标准药物治疗。试验因高交叉率和招募不佳提前终止。
要点
- 血管内治疗未显著改善椎基底动脉闭塞患者90天功能结局。
- 实际接受血管内治疗者功能结局优于单纯标准治疗。
- 两组90天死亡率无显著差异。
核心结论
- 椎基底动脉闭塞患者接受血管内治疗与单纯标准药物治疗相比, favourable outcomes无显著差异。
研究设计与样本
- 多中心、随机、开放标签、盲法结局评估试验,在中国28个中心进行,计划纳入椎基底动脉闭塞8小时内患者。
- 因高交叉率和招募不佳,试验在随机131例(干预组66例,对照组65例)后提前终止。
临床怎么用
- 对于椎基底动脉闭塞患者,血管内治疗未显示明确获益,临床决策需个体化。
- 实际接受血管内治疗的患者功能结局可能更好,但需考虑试验局限性。
局限性
- 试验因高交叉率和招募不佳提前终止,样本量减少。
- 试验过程中 equipoise 丧失导致对分配治疗依从性差,可能混杂结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous randomised trials have shown an overwhelming benefit of mechanical thrombectomy for treating patients with stroke caused by large vessel occlusion of the anterior circulation. Whether endovascular treatment is beneficial for vertebrobasilar artery occlusion remains unknown. In this study, we aimed to investigate the safety and efficacy of endovascular treatment of acute strokes due to vertebrobasilar artery occlusion. METHODS: We did a multicentre, randomised, open-label trial, with blinded outcome assessment of thrombectomy in patients presenting within 8 h of vertebrobasilar occlusion at 28 centres in China. Patients were randomly assigned (1:1) to endovascular therapy plus standard medical therapy (intervention group) or standard medical therapy alone (control group). The randomisation sequence was computer-generated and stratified by participating centres. Allocation concealment was implemented by use of sealed envelopes. The primary outcome was a modified Rankin scale (mRS) score of 3 or lower (indicating ability to walk unassisted) at 90 days, assessed on an intention-to-treat basis. The primary safety outcome was mortality at 90 days. Secondary safety endpoints included the rates of symptomatic intracranial haemorrhage, device-related complications, and other severe adverse events. The BEST trial is registered with ClinicalTrials.gov, NCT02441556. FINDINGS: Between April 27, 2015, and Sept 27, 2017, we assessed 288 patients for eligibility. The trial was terminated early after 131 patients had been randomly assigned (66 patients to the intervention group and 65 to the control group) because of high crossover rate and poor recruitment. In the intention-to-treat analysis, there was no evidence of a difference in the proportion of participants with mRS 0-3 at 90 days according to treatment (28 [42%] of 66 patients in the intervention group vs 21 [32%] of 65 in the control group; adjusted odds ratio [OR] 1·74, 95% CI 0·81-3·74). Secondary prespecified analyses of the primary outcome, done to assess the effect of crossovers, showed higher rates of mRS 0-3 at 90 days in patients who actually received the intervention compared with those who received standard medical therapy alone in both per-protocol (28 [44%] of 63 patients with intervention vs 13 [25%] of 51 with standard therapy; adjusted OR 2·90, 95% CI 1·20-7·03) and as-treated (36 [47%] of 77 patients with intervention vs 13 [24%] of 54 with standard therapy; 3·02, 1·31-7·00) populations. The 90-day mortality was similar between groups (22 [33%] of 66 patients in the intervention vs 25 [38%] of 65 in the control group; p=0·54) despite a numerically higher prevalence of symptomatic intracranial haemorrhage in the intervention group. INTERPRETATION: There was no evidence of a difference in favourable outcomes of patients receiving endovascular therapy compared with those receiving standard medical therapy alone. Results might have been confounded by loss of equipoise over the course of the trial, resulting in poor adherence to the assigned study treatment and a reduced sample size due to the early termination of the study. FUNDING: Jiangsu Provincial Special Program of Medical Science.
引用
- Liu X, Dai Q, Ye R, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol. 2019. PMID: 31831388. doi:10.1016/S1474-4422(19)30395-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。